Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMarin buys ZyStor for $22mm plus potential earnouts

Executive Summary

BioMarin Pharmaceutical Inc. (orphan diseases) is paying $22mm up front in cash to acquire private biotech ZyStor Therapeutics Inc., which is focused on enzyme replacement therapies (ERT) for lysosomal storage disorders. BioMarin could spend another $93mm if certain development, regulatory, and commercial milestones are met.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies